145 related articles for article (PubMed ID: 21115792)
1. In vitro activity and in vivo efficacy of posaconazole in treatment of murine infections by different isolates of the Aspergillus terreus complex.
Salas V; Pastor FJ; Rodríguez MM; Calvo E; Mayayo E; Guarro J
Antimicrob Agents Chemother; 2011 Feb; 55(2):676-9. PubMed ID: 21115792
[TBL] [Abstract][Full Text] [Related]
2. Evaluating posaconazole dosing regimens of the different formulations against Aspergillus spp. in adults: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation.
Wei XC; Zhao MF; Li X; Xiao X
Int J Antimicrob Agents; 2020 Oct; 56(4):106112. PubMed ID: 32721598
[TBL] [Abstract][Full Text] [Related]
3. Are epidemiologic cut-off values predictors of the in vivo efficacy of azoles in experimental aspergillosis?
Calvo E; Pastor FJ; Sutton DA; Fothergill AW; Rinaldi MG; Salas V; Guarro J
Diagn Microbiol Infect Dis; 2012 Oct; 74(2):158-65. PubMed ID: 22858549
[TBL] [Abstract][Full Text] [Related]
4. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial.
Walsh TJ; Raad I; Patterson TF; Chandrasekar P; Donowitz GR; Graybill R; Greene RE; Hachem R; Hadley S; Herbrecht R; Langston A; Louie A; Ribaud P; Segal BH; Stevens DA; van Burik JA; White CS; Corcoran G; Gogate J; Krishna G; Pedicone L; Hardalo C; Perfect JR
Clin Infect Dis; 2007 Jan; 44(1):2-12. PubMed ID: 17143808
[TBL] [Abstract][Full Text] [Related]
5. MIC values of voriconazole are predictive of treatment results in murine infections by Aspergillus terreus species complex.
Salas V; Pastor FJ; Sutton DA; Calvo E; Mayayo E; Fothergill AW; Rinaldi MG; Guarro J
Antimicrob Agents Chemother; 2013 Mar; 57(3):1532-4. PubMed ID: 23295929
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene.
Mavridou E; Brüggemann RJ; Melchers WJ; Mouton JW; Verweij PE
Antimicrob Agents Chemother; 2010 Feb; 54(2):860-5. PubMed ID: 19917751
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Aspergillus terreus infections: a clinical problem not yet resolved.
Pastor FJ; Guarro J
Int J Antimicrob Agents; 2014 Oct; 44(4):281-9. PubMed ID: 25190543
[TBL] [Abstract][Full Text] [Related]
8. Clinical isolates of Aspergillus species remain fully susceptible to voriconazole in the post-voriconazole era.
Guinea J; Recio S; Peláez T; Torres-Narbona M; Bouza E
Antimicrob Agents Chemother; 2008 Sep; 52(9):3444-6. PubMed ID: 18606840
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the Sensititre YeastOne and CLSI M38-A2 Microdilution Methods in Determining the Activity of Amphotericin B, Itraconazole, Voriconazole, and Posaconazole against Aspergillus Species.
Wang HC; Hsieh MI; Choi PC; Wu CJ
J Clin Microbiol; 2018 Oct; 56(10):. PubMed ID: 30093391
[TBL] [Abstract][Full Text] [Related]
10. Experimental efficacy of anidulafungin against Aspergillus terreus species complex.
Sanchis M; Capilla J; Mayayo E; Pastor FJ; Guarro J
Med Mycol; 2015 Aug; 53(6):630-5. PubMed ID: 25980004
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of caspofungin against Aspergillus terreus.
Barchiesi F; Spreghini E; Santinelli A; Fothergill AW; Fallani S; Manso E; Pisa E; Giannini D; Novelli A; Cassetta MI; Mazzei T; Rinaldi MG; Scalise G
Antimicrob Agents Chemother; 2005 Dec; 49(12):5133-5. PubMed ID: 16304185
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida.
Cacciapuoti A; Loebenberg D; Corcoran E; Menzel F; Moss EL; Norris C; Michalski M; Raynor K; Halpern J; Mendrick C; Arnold B; Antonacci B; Parmegiani R; Yarosh-Tomaine T; Miller GH; Hare RS
Antimicrob Agents Chemother; 2000 Aug; 44(8):2017-22. PubMed ID: 10898669
[TBL] [Abstract][Full Text] [Related]
13. Dihydroorotate dehydrogenase inhibitor olorofim exhibits promising activity against all clinically relevant species within Aspergillus section Terrei.
Lackner M; Birch M; Naschberger V; Grässle D; Beckmann N; Warn P; Gould J; Law D; Lass-Flörl C; Binder U
J Antimicrob Chemother; 2018 Nov; 73(11):3068-3073. PubMed ID: 30351438
[TBL] [Abstract][Full Text] [Related]
14. Luliconazole, an alternative antifungal agent against Aspergillus terreus.
Zargaran M; Taghipour S; Kiasat N; Aboualigalehdari E; Rezaei-Matehkolaei A; Zarei Mahmoudabadi A; Shamsizadeh F
J Mycol Med; 2017 Sep; 27(3):351-356. PubMed ID: 28483449
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of posaconazole in murine experimental sporotrichosis.
Fernández-Silva F; Capilla J; Mayayo E; Guarro J
Antimicrob Agents Chemother; 2012 May; 56(5):2273-7. PubMed ID: 22330929
[TBL] [Abstract][Full Text] [Related]
16. Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.
Rodríguez MM; Pastor FJ; Sutton DA; Calvo E; Fothergill AW; Salas V; Rinaldi MG; Guarro J
Antimicrob Agents Chemother; 2010 May; 54(5):1665-9. PubMed ID: 20145077
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of oleylphosphocholine (OlPC) in vitro and in a mouse model of invasive aspergillosis.
Paulussen C; Boulet G; Bosschaerts T; Cos P; Fortin A; Maes L
Mycoses; 2015 Mar; 58(3):127-32. PubMed ID: 25590577
[TBL] [Abstract][Full Text] [Related]
18. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000.
Pfaller MA; Messer SA; Hollis RJ; Jones RN;
Antimicrob Agents Chemother; 2002 Apr; 46(4):1032-7. PubMed ID: 11897586
[TBL] [Abstract][Full Text] [Related]
19. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B.
Walsh TJ; Petraitis V; Petraitiene R; Field-Ridley A; Sutton D; Ghannoum M; Sein T; Schaufele R; Peter J; Bacher J; Casler H; Armstrong D; Espinel-Ingroff A; Rinaldi MG; Lyman CA
J Infect Dis; 2003 Jul; 188(2):305-19. PubMed ID: 12854088
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of posaconazole for chronic pulmonary aspergillosis.
Felton TW; Baxter C; Moore CB; Roberts SA; Hope WW; Denning DW
Clin Infect Dis; 2010 Dec; 51(12):1383-91. PubMed ID: 21054179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
